Analogs of the pancreatic peptide hormone amylin are making strides in obesity as developers zoom in on oral drugs that can emulate or even improve on injectable GLP-1 agonists while avoiding muscle loss and gastrointestinal troubles. Access options Access Nature and 54 other Nature Portfolio journals Get Nature+, our best-value online-access subscription 27,99 € / 30 days cancel...
FlashNews:
Razer’s new USB-C earbuds bring back wired audio, complete with RGB lighting
Smart packaging film ‘lights up’ under UV as meat loses freshness
Anthropic IPO valuation talks drop to $1.3T
The Anker Solix S5000 Can Power Your Home For 48 Hours – Here’s What It Costs
Mysterious Gas over Mars’ Alba Mons Could Hint at Volcanic Activity
Lemmings CSS Animation
Microsoft Project Professional 2024 drops to $40 for a lifetime
These 10 New Features Are Coming to iOS 27.3
Students gather to explore Hawaii’s glorious night sky | Space photo of the day for Nov. 4, 2026
This Baseus 100W 3-port charger is $46, near its all-time
Apple Watch’s always-listening AI tools arrive in the iOS 27.3 beta
These 3 vibe-coded operating systems could be another Windows alternative one day
Start your adventure with 50% off the Citizen Promaster Dive Eco-Drive
Forget hobby drones: College student builds 491 mph jet-powered speed demon
A NASA telescope will likely plummet to Earth on Friday
Google’s AI can turn almost anything you read into a
Jack Nicholson’s Only Sci-Fi Movie Was An Underappreciated ’90s Classic
Backup by Biolite Review: A Cool Idea
An exclusive conversation with the developer of REA, the viral AI reverse engineering tool
Home
amylin-based